ASH 2022 | An update on GRIFFIN: D-RVd in patients with newly diagnosed multiple myeloma
Ajai Chari, MD, Mount Sinai School of Medicine, New York City, NY, discusses results from the GRIFFIN phase II trial (NCT02874742) for daratumumab in combination with lenalidomide, bortezomib, and dexamethasone (RVd) in the treatment of transplant-eligible, newly diagnosed multiple myeloma (NDMM). The study reported a benefit for the addition of daratumumab in all patients with respect to measurable residual disease (MRD) negativity and progression-free survival (PFS), with the exception of two high-risk patient subgroups. This interview took place at the 64th ASH Annual Meeting and Exposition Congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Paid Consultant for Janssen
